Monoclonal antibodies make up most of the immune checkpoint inhibitors and are designed to precisely target cancer cells by blocking the checkpoint proteins, programmed cell death protein-1 (PD-1), and PD-ligand (L)1. Here, PDCD1 is linked to cancer.